Gelteq Limited Ordinary Shares logo

Gelteq Limited Ordinary Shares(GELS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GELS

11/13/2026: GELS (1-star) is currently NOT-A-BUY. Pass it for now.

Gelteq Limited is a micro-cap biotechnology and specialty delivery company that develops white-label edible gel solutions for pharmaceuticals, nutraceuticals, pet care, and sports nutrition. The company's primary strength lies in its proprietary gel technology designed to simplify high-dosage administration and address swallowing difficulties. Its main investment opportunity centers on scaling commercial white-label partnerships and advancing pharmaceutical pipelines through streamlined regulatory pathways. However, the company faces significant risks, including very limited revenue scale, ongoing operational cash burn, and intense market competition. GELS suits speculative growth investors willing to monitor execution milestones and liquidity management closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitGelteq offers early-stage expansion potential in alternative drug delivery, but current revenue scale is very small.
Momentum investorStrong fit while signal remains positiveLow market capitalization can occasionally drive sharp speculative moves when positive news flow emerges.
Value investorWeak fitOngoing net losses and lack of positive earnings make traditional value metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for operations.
Low-risk investorWeak fitHigh share price volatility and nano-cap liquidity risks expose investors to substantial capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThin trading volume and nano-cap status lead to sharp daily price swings.
Valuation riskHighStock pricing is heavily sentiment-driven due to minimal current revenue.
Competition risk (specialty delivery and pharma)Medium / highThe company contends with well-resourced alternative drug delivery competitors.
Business qualityMediumInnovative gel technology is offset by early commercial maturity.
Dividend incomeLow / noneNo cash distribution policy is in place for income-seeking investors.
Execution riskHighSuccess relies entirely on securing commercial white-label clients and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.07M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 66.3K shares
Beta -0.36
52 Weeks Range 0.38 - 2.01
Updated Date 11/15/2026
52 Weeks Range 0.38 - 2.01
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.44

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -38.33%
Avg. Invested days 2
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GELS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft analyst coverage.

Company Fundamentals

★★★★★
GELS has soft overall fundamentals (2 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-87.4%), weak cash generation (FCF margin -3721.1%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
GELS's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 3417.7% of revenue). Liquidity is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
GELS's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-87.4%, negative) and free-cash-flow growth (-405.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.0% (soft) and 48.1% of outstanding shares are publicly tradable (moderate). Insider ownership of 47.53% supports management-shareholder alignment.

Top 5 Institutional Investors

TWO SIGMA SECURITIES, LLC 0.31%
Jane Street Group LLC 0.28%
Wedbush Morgan Securities Inc 0.19%
Morgan Stanley - Brokerage Accounts 0.14%
Citadel Advisors Llc 0.11%

Unit Economics (Per $1K Revenue)

★★★★★
GELS generates approximately $1,000 of gross profit, $-33,177 of operating income, and $-37,211 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
GELS has a relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
White-Label Product SalesSelling formulated gel products in bulk or finished package forms to third-party brand owners who market them.Gelteq acts as a business-to-business developer licensing or manufacturing specialized gel formats for others to sell.
Geographic Markets (US, China, Australia)Commercial development and partnership activities spanning North America, Asia-Pacific, and domestic Australian markets.Revenue sources are geographically diversified across emerging international partnerships.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 7.72M
Price to Sales(TTM) 8.63
Enterprise Value 7.72M
Price to Sales(TTM) 8.63
Enterprise Value to Revenue 68.16
Enterprise Value to EBITDA -
Shares Outstanding 10.71M
Shares Floating 5.15M
Shares Outstanding 10.71M
Shares Floating 5.15M
Percent Insiders 47.53
Percent Institutions 0.98

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.